Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol.
Dexanabinol [HU 211, dexanabinone, sinnabidol, PA 50211, PRS 211007] is a synthetic, non-psychotropic tetrahydro-cannabinoid. Dexanabinol lacks cannabimimetic activity, and is a functional antagonist of the NMDA receptor with antioxidant and anti-tumour necrosis factor-alpha properties. Dexanabinol is in clinical trials for traumatic brain injury (head injuries), glaucoma and mild cognitive impairment, and is being investigated preclinically for its potential in the treatment of multiple sclerosis. Pharmos has a licensing agreement with the Hebrew University, Israel, and is seeking a partner for development and commercialisation of the dexanabinol family of compounds. The Financial Times (ft.com) reported in March 2001 that the market for brain trauma could be worth approximately 500 million US dollars, according to estimates by Pharmos. The company was said to have 26 million US dollars in capital at the time, most of which would be used taking dexanabinol through regulatory submission, according to the Financial Times.
D000818:Animals; D002986:Clinical Trials as Topic; D006259:Craniocerebral Trauma / Q000188:drug therapy; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D015507:Drugs, Investigational; D016194:Receptors, N-Methyl-D-Aspartate; D014409:Tumor Necrosis Factor-alpha; D013759:Dronabinol; C062018:HU 211